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Genome-wide association studies (GWAS) have identified genetic variants associated with
numerous cardiovascular and metabolic diseases. Newly identified polymorphisms associ-
ated with myocardial infarction, dyslipidemia, hypertension, diabetes, and insulin resistance
suggest novel mechanistic pathways that underlie these and other complex diseases.Work-
ing out the connections between the polymorphisms identified in GWAS and their biological
mechanisms has been especially challenging given the number of non-coding variants iden-
tified thus far. In this review, we discuss the utility of expression quantitative trait locus
(eQTL) databases in the study of non-coding variants with respect to cardiovascular and
metabolic phenotypes. Recent successes in using eQTL data to link variants with functional
candidate genes will be reviewed, and the shortcomings of this approach will be outlined.
Finally, we discuss the emerging next generation of eQTL studies that take advantage of
the ability to generate induced pluripotent stem cell lines from population cohorts.
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Genome-wide association studies (GWAS) of common cardio-
vascular disease have successfully identified many new genetic
loci that explain the heritability of myocardial infarction, dyslipi-
demia, hypertension, and diabetes (Hirschhorn, 2009). However,
there is a substantial gap between single nucleotide polymorphism
(SNP) associations discovered by GWAS and understanding how
the locus contributes to disease. Only rarely does a SNP have a
clear mechanistic relationship, such as when the polymorphism
lies in the coding sequence of a gene and alters protein function,
as has been observed with NOD2 (nucleotide-binding oligomer-
ization domain containing-2) mutations in inflammatory bowel
disease (Hugot et al., 2001). A large number of GWAS hits lie in
intergenic or intronic regions, where the link between variant and
protein function is more circumspect.
Variation in gene expression is likely a major mechanism under-
lying susceptibility to complex diseases that is captured in many
GWAS hits. A polymorphism in a regulatory element, for example,
can alter the abundance of a gene transcript. The linkage disequi-
librium based identification of loci for gene expression is termed
expression quantitative trait locus (eQTL) mapping. Simply put,
it is the combination of mRNA expression and genotype data to
determine which variants correlate with transcript levels of genes.
In principle, eQTLs can be mapped for known SNPs in any tissue
type of interest. When the regulatory effect of a polymorphism
is on a nearby gene the relationship is termed cis, whereas dis-
tant effects are termed trans. eQTL data can elucidate mechanisms
underlying biological control of gene expression and the genes
involved in disease pathogenesis.
Application of eQTL data to animal models and large human
databases has established the heritability of gene expression
(Dixon et al., 2007; Emilsson et al., 2008; Ding et al., 2010; Inno-
centi et al., 2011; Min et al., 2011). Furthermore, it has been shown
that many common trait-associated variants act by altering tran-
script levels (Nicolae et al., 2010). Thus the use of eQTL data can
provide the link between a SNP of interest and its responsible cod-
ing gene, and it is a reasonable initial line of inquiry in the search
for functionally significant SNPs.
eQTL ANALYSES AND BLOOD CHOLESTEROL LEVELS
A recent study used eQTL data to elucidate the relationship
between a non-coding GWAS variant in a chromosome 1p13.3
locus associated with low-density lipoprotein (LDL) cholesterol
and the hepatic expression of the SORT1 gene (Musunuru et al.,
2010). To determine if SNPs in the 1p13.3 locus were cis-acting reg-
ulators of nearby genes, expression levels were measured in liver,
subcutaneous fat, and omental fat human tissue samples. After
a large-scale analysis showed association between a representa-
tive SNP (rs646776) and transcript levels of three genes (CELSR2,
PSRC1, and SORT1) in liver, a targeted eQTL analysis was per-
formed in a replication cohort of 62 human liver samples. Minor
allele homozygotes displayed more than 12-fold higher SORT1
expression than major allele homozygotes. This differential gene
expression by genotype was not apparent in the analysis of the
adipose samples or in previously reported data from lympho-
cytes (Linsel-Nitschke et al., 2010), suggesting that the mechanism
underlying the allele-specific gene expression is liver-specific. This
finding paved the way for in vivo experiments modulating liver
gene expression with siRNA or viral overexpression vectors, which
established that Sort1 alters blood LDL cholesterol levels by mod-
ulating hepatic lipoprotein particle secretion (Musunuru et al.,
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2010). The other two genes in the locus – CELSR2 and PSRC1 –
were excluded as causal genes either through human eQTL data
(CELSR2) or with similar in vivo viral overexpression in mice in
mice (PSRC1; Musunuru et al., 2010).
With the successful use of eQTL data to link SORT1 to cho-
lesterol biology, the same approach is being utilized to uncover
more genes of biological significance. Besides the SORT1 locus,
GWAS for blood cholesterol levels have also uncovered at least
94 other associated loci (Teslovich et al., 2010). To gain insight
into how DNA variants in each of these loci might influence bio-
logically relevant pathways, eQTL analysis was performed with
RNA expression profiling of >39,000 transcripts in liver, omental
fat, and subcutaneous fat. At a standard threshold of statisti-
cal significance (P < 5× 10−8), 38 SNP-to-gene eQTLs in liver,
28 in omental fat, and 19 in subcutaneous fat were identified.
Some lead SNPs were shown to be remote from their associated
gene transcripts. For example, rs9987289 [associated with LDL-C
and high-density lipoprotein (HDL)-C] correlated with a twofold
change in liver expression of PPP1R3B, yet is 174 kb away from
the gene. Similarly, rs2972146 correlated with IRS1 expression in
omental fat, despite being located 495 kb away from the gene. The
eQTL data for these two loci provide another layer of insight into
their biological significance.
These eQTL data were also used to nominate two additional
genes for functional validation, the aforementioned PPP1R3B,
and the TTC39B gene, each of which lies in or in proximity to
a locus associated with HDL cholesterol (Teslovich et al., 2010).
Although there are other genes at the loci in question, strong eQTL
relationships between the lead SNPs and gene expression were
only observed with PPP1R3B and TTC39B. Experiments in which
the hepatic expression of each of the two genes was modulated
in mouse liver established that they are both indeed regulators
of blood HDL cholesterol levels and therefore are causal genes
underlying the GWAS associations.
eQTL ANALYSES TO UNCOVER NOVEL MECHANISMS IN
NEW CELL TYPES
One exciting prospect of GWAS is uncovering novel pathways
and mechanistic insights into disease pathogenesis. With coro-
nary artery disease (CAD), eQTL analyses in novel cell types are
being undertaken to link genetic associations with pathways in
inflammation and thrombosis. Monocytes represent one such cell
type; its relative accessibility (from blood samples) and ease of use
in eQTL studies make it an attractive cell type in which to link
genotype and expression data, though it represents only one of the
full spectrum of cell types that need to be studied to comprehen-
sively find novel mechanisms for cardiovascular disease. One study
linked two SNPs on chromosome 10q23.31 with increased CAD
risk and increased LIPA mRNA expression in monocytes (Wild
et al., 2011). The investigators began with a GWAS of 2,078 CAD
cases vs. 2,953 control individuals and then went on to test all SNPs
that reached genome-wide significance with monocyte transcripts
in cis and trans. They found associations between LIPA mRNA
transcript levels and low HDL cholesterol (P = 2.5× 10−3) as
well as impaired endothelial function measured by flow-mediated
vasodilation, but not with traditional risk factors, LDL cholesterol,
or triglycerides.
A second CAD-associated SNP did not show association with
transcript expression in liver, whole blood, or monocytes, but
instead was strongly associated with expression in aortic media,
aortic adventitia, and mammary artery tissue (Folkersen et al.,
2010). This SNP, located 117 kb downstream of the PDGFD gene
(Coronary Artery Disease , C4D), highlights the necessity of study-
ing multiple cell types for expression data if the goal is to elucidate
novel mechanistic pathways for complex diseases.
LIMITATIONS OF eQTL ANALYSES
For all the early success of eQTL analyses in uncovering new disease
genes, the number of unresolved mechanistic links between SNPs
and gene expression highlight the shortcomings of these data. Here
we will discuss the technical and conceptual limitations of eQTL
analysis, as well as the implications of and potential answers to
these limitations.
IDENTIFIED eQTLs DO NOT ALWAYS LEAD TO DIRECT BIOLOGICAL
INTERPRETATION
Single nucleotide polymorphisms in the CAD-associated chromo-
some 9p21.3 locus – by far the strongest population-wide genetic
contributor to CAD – have evaded mechanistic understanding
though they are associated with not just CAD but also aneurysms,
vascular disease, and multiple cancers (Helgadottir et al., 2008).
From monocyte-derived eQTL data, there appear to be cis rela-
tionships with nearby genes CDKN2A, CDKN2B, and ANRIL
(Cunnington et al., 2010). But these data do little to elucidate the
mechanism by which the 9p21 locus contributes to disease. For a
biologic connection between a SNP and a mechanism of disease
much more experimentation is required; though eQTL analysis
may provide the initial insight.
TECHNICAL LIMITATIONS: PLATFORM COVERAGE, BATCH VARIATION,
SAMPLE SIZE, AND TISSUE AVAILABILITY
There currently exist several commercial platforms by which
expression data is obtained. The coverage of each platform is
variable, and each is subject to its individual errors. This vari-
ability results in batch-to-batch variation between analyses that
should otherwise be consistent. This was observed in a report of
large-scale differences in gene expression between ethnic groups
(Akey et al., 2007). In this case, the highly significant differences
were found to be due to the separate processing of lymphoblas-
toid cell lines (LCLs) from subjects of European vs. Asian ancestry.
Different microarray platforms only have 30–40% overlap in tran-
script detection (Barnes et al., 2005; Pedotti et al., 2008). With
the advent of direct ultra-high-throughput sequencing of RNA
transcripts (RNA-seq), analyses of gene expression are expected
to improve; however, handling the terabytes of data generated by
such approaches will be a challenge in its own right.
Suggested solutions for batch-to-batch variation include exper-
imental and statistical approaches. Efforts should be made to
spread sample groups across different processing times to limit
this as a confounding variable. To correct for batch effects with sta-
tistical analyses, the possible variable that could contribute should
be identified and reported. Published results, for example, should
report the processing group and time of samples in a study (Leek
et al., 2010).
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Many eQTL databases are limited to a few 100 human sam-
ples because of cost and difficulty in obtaining tissue. This results
in nominal P values in most eQTL analyses that are difficult to
interpret (Schadt et al., 2003; Morley et al., 2004). To rectify this
limitation, the National Institutes of Health have launched a 2-
year pilot project to build a more comprehensive bank of samples
termed the Genotype-Tissue Expression project (GTEx). To date,
no project has analyzed genetic variation and expression in as
many tissues in such a large cohort as planned for GTEx. If com-
pleted, GTEx will house samples of 30 different tissues from 1,000
donors. Even with this large databank, however, questions remain
such as whether healthy or diseased samples should be collected
together (Cookson et al., 2009).
The fact that many eQTL studies are conducted in LCLs is both
a technical and conceptual shortcoming. LCLs form the basis for
numerous gene expression studies because they represent an eas-
ily banked source of nucleic acids for genetic studies (Cookson
et al., 2009). LCLs, however, exhibit genomic instability with mul-
tiple passages of storage and regrowth. Furthermore, LCLs likely
have unique, tissue-specific expression profiles that may not reflect
normal human biology. The predominance of clonal cell popula-
tions, for example, can result in random patterns of monoallelic
expression (Plagnol et al., 2008). There is recent evidence, how-
ever, that other cell types have expression overlap with LCLs. In
fact, 70% of cis-eQTLs in LCLs are shared with skin cells (Ding
et al., 2010). This finding can allow for comparisons between tis-
sue types, and conclusions about the functional importance of
variants can potentially be made on this basis.
Even when eQTL studies use cells other than LCLs, there are
inherent biases as a result of the limitations of tissue ascertainment.
Many of the studies that profile liver and adipose expression use
human samples obtained during surgeries (Schadt et al., 2008); it
stands to reason that these were from non-healthy patients under-
going surgery for non-research-related reasons, since it would be
unethical to perform such biopsies in healthy individuals. Thus the
samples do not represent the general population, nor could they
be ascertained a priori on the basis of particular genotypes or phe-
notypes of interest. Furthermore, the samples were limited in size,
non-renewable, and could not be used to generate large numbers
of cultured hepatocytes and adipocytes, since unlike LCLs primary
hepatocytes and adipocytes cannot be sustained for long in tissue
culture conditions.
FUTURE DIRECTIONS
The full spectrum of gene expression that relates to disease involves
not only many cell types but different conditions for these cells
to “exercise the genome.” There is evidence that environmental
actions on gene expression are profound in humans, and, where
possible, future eQTL studies should incorporate environmental
stimuli. Model stimuli that could be tested in an in vitro sys-
tem include pro-inflammatory stresses, metabolic stresses (such
as hypoglycemia or hypoxia), the response to radiation, and
even response to drugs, hormones, and peptides (Cookson et al.,
2009).
The next generation of eQTL studies will have the ability to uti-
lize induced pluripotent stem cells (iPSCs) as a renewable source
of patient-specific cell lines. Recent advances in nuclear repro-
gramming technology allow for the transformation of terminally
differentiated adult cells into induced iPSCs that are phenotypi-
cally indistinguishable from embryonic stem cells (Takahashi et al.,
2007). This leap forward makes possible the creation of patient-
specific iPSC lines that, by definition, can be maintained in culture
indefinitely. Gene expression profiling from these patient-specific
cell lines will allow larger-scale gene analyses from patients in
whom complete phenotype data is available.
As one example, an effort is now underway to create iPSCs from
blood samples from up to 3,000 participants in the Framingham
Heart Study (FHS), which is a unique, community-based cohort
in which three generations of individuals have been extensively
phenotyped and genotyped. Although limited eQTL analyses have
been performed within the FHS (Levy et al., 2009; Fox et al., 2011),
these analyses suffer from the standard pitfalls of underpowered
results and suboptimal tissue types. With iPSCs, the full spectrum
of gene expression can be extensively profiled in any tissue that
can be differentiated from the cell lines, allowing investigators to
study tissue types that in ordinary circumstances would be pro-
hibitive to obtain from living human beings. In the planned pilot
studies, a subset of the FHS iPSC lines will be differentiated into
hepatocytes and adipocytes – two tissues of relevance to cardio-
vascular and metabolic diseases – followed by whole-genome gene
expression profiling, which will pave the way for eQTL analyses of
unprecedented size and rigor.
CONCLUSION
Gene expression analyses can yield important information about
genetic architecture and can point to mechanisms that link genet-
ics and cardiovascular disease. The application of eQTL analyses
has already forged connections between GWAS data and mech-
anistic pathways. Technical and conceptual limitations, however,
limit the ability to systemize this approach to more polymorphisms
for more diseases. The advent of more comprehensive biobanks,
high-throughput RNA sequencing, and collections of iPSC lines
holds much promise for the field. Ultimately, the ability to explain
the heritability of common diseases such as cardiovascular and
metabolic disorders should be greatly facilitated by future eQTL
efforts.
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